5 Key Takeaways
-
1
Aptamer-functionalized contact lenses enhance drug delivery to the eye by improving targeting specificity and retention time on the ocular surface.
-
2
Aptamers, with low immunogenicity and high specificity, are ideal for ophthalmic drug delivery and have been integrated into contact lenses for this purpose.
-
3
The FDA has approved two anti-VEGF aptamers, marking significant advancements in the use of aptamers for treating ocular diseases.
-
4
Incorporating biosensors into contact lenses could enable real-time monitoring of ocular or systemic diseases through noninvasive methods.
-
5
Key challenges for clinical translation of aptamer-functionalized contact lenses include stability in tear fluid and ensuring lens comfort and biocompatibility.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
